Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 19,078 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Clear all
Completed Not applicable Interventional

Modified Atkins Diet Plus KetoCal for Adult Epilepsy

NCT01834482
View directory record Official record
Conditions
Epilepsy, Seizure, Medically Resistant Epilepsy, Medically Resistant Seizures
Interventions
Modified Atkins diet, KetoCal
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

NCT00387959
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, rituximab, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 18, 2026, 1:10 AM EDT
Recruiting Phase 1 Interventional

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

NCT04485559
View directory record Official record
Conditions
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High-Grade Glioma (HGG)
Interventions
Everolimus, Trametinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 18, 2026, 1:10 AM EDT
Terminated Not applicable Interventional

L-Tyrosine Supplementation in Patients With Fibromyalgia

NCT01219049
View directory record Official record
Conditions
Fibromyalgia
Interventions
Tyrosine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BMS-986012 in Relapsed/Refractory SCLC

NCT02247349
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
BMS-986012 (anti-fucosyl-GM1), Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure

NCT00853658
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Enalapril, Aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
58
States / cities
Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 18, 2026, 1:10 AM EDT
Active, not recruiting Phase 1 Interventional

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
Livmoniplimab, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 18, 2026, 1:10 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of Auditory Cues on Mood and Gait

NCT05048576
View directory record Official record
Conditions
Psychological, Auditory Perception
Interventions
Negative Reinforcement, Positive Reinforcement, Silence, Music
Behavioral
Lead sponsor
Clarkson University
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Potsdam, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows

NCT00752050
View directory record Official record
Conditions
Glabellar Rhytides, Frown Lines Between the Eyebrows
Interventions
Mentor Purified Toxin Botulinum Toxin Type A, Preservative-free Saline
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

NCT00295750
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide 7.5 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
23
States / cities
Homewood, Alabama • Anchorage, Alaska • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Not applicable Interventional Results available

Effect of Low Carbohydrate Versus Low Fat Diet in the Treatment of Dyslipidemia in Obese Children With Metabolic Syndrome

NCT03937960
View directory record Official record
Conditions
Metabolic Syndrome, Obesity, Dyslipidemias
Interventions
Carbohydrate restricted group, Standard low fat diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
10 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

NCT00935220
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
linagliptin QD (once daily) for 7 days
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
21 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
6
States / cities
Cypress, California • DeLand, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 18, 2026, 1:10 AM EDT
Not listed Phase 2 Interventional

A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

NCT00931840
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
EZN-2208, Cetuximab and Irinotecan
Drug
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
35
States / cities
Tucson, Arizona • Alhambra, California • Bakersfield, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

NCT00796068
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelodysplastic Syndrome (MDS)
Interventions
Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation, Treosulfan, Umbilical Cord Blood Transplantation
Drug · Other · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
3
States / cities
Aurora, Colorado • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Phase 1 Interventional

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

NCT01031368
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
cytarabine, clofarabine, filgrastim, Ex-vivo expanded cord blood progenitor cell infusion, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Nohla Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

NCT01322490
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
PROSTVAC-V, PROSTVAC-F, GM-CSF, GM-CSF Placebo, Placebo
Biological · Drug · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
84
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Berkeley, California + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

NCT00500110
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Imatinib Mesylate, Leuprolide, Goserelin Acetate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Not applicable Interventional

Adjuvant Oxytocin for Preinduction Ripening With a Foley catheter--a Clinical Trial

NCT00468520
View directory record Official record
Conditions
Pregnancy, Induced Labor, Cervical Ripening
Interventions
low dose oxytocin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Not applicable Interventional Results available

Mechanisms of Insulin Facilitation of Memory

NCT01145482
View directory record Official record
Conditions
Memory Disorders
Interventions
Insulin, Saline
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 18, 2026, 1:10 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

NCT03865082
View directory record Official record
Conditions
Solid Tumor
Interventions
Tilsotolimod, Nivolumab, Ipilimumab
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Tucson, Arizona • Newport Beach, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 18, 2026, 1:10 AM EDT
Not listed Phase 3 Interventional

Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma

NCT00816959
View directory record Official record
Conditions
Hodgkin's Lymphoma
Interventions
R-mabHDI and ABVD, ABVD
Drug
Lead sponsor
American Scitech International
Other
Eligibility
16 Years to 65 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
East Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Phase 3 Interventional

Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis

NCT00002070
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Sargramostim, Ganciclovir
Drug
Lead sponsor
Schering-Plough
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Sherman Oaks, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

NCT03897205
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Imlifidase, Plasma Exchange
Drug · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 18, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

NCT01844505
View directory record Official record
Conditions
Unresectable or Metastatic Melanoma
Interventions
Nivolumab, Ipilimumab, Placebo for Nivolumab, Placebo for Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
46
States / cities
Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 18, 2026, 1:10 AM EDT